Table 2.

Effects of pentoxifylline (PTX, a cytokine blocker, 30 mg/kg, IP) treatment on metabolic and anatomic data in rats after HFD consumption for 17 weeks

Parameters	Control	Control + PTX	OH	OH + PTX
BW (g)	559 ± 41	548 ± 43	688 ± 51*	645 ± 49
Plasma glucose (mg/dl)	126 ± 12	122 ± 11	147 ± 16	142 ± 15
Plasma insulin (ng/ml)	1.51 ± 0.3	1.48 ± 0.3	3.12 ± 0.31*	2.09 ± 0.27#
Plasma cholesterol (mg/dl)	43.1 ± 4.1	42.0 ± 3.9	61.2 ± 6.5*	58.3 ± 5.7
Plasma triglyceride (mg/dl)	66.9 ± 6.6	65.8 ± 7.2	92.6 ± 9.3*	85.2 ± 7.9
HW (mg)	1609 ± 91	1610 ± 112	2218 ± 132*	2021 ± 121
HW/BW (mg/g)	2.91 ± 0.27	2.94 ± 0.35	3.22 ± 0.37	3.13 ± 0.40
Sum of WAT mass (g)	28.5 ± 3.1	27.7 ± 3.3	63.6 ± 5.9*	57.9 ± 4.2

Sum of WAT mass includes inguinal, retroperitoneal, epididymal and mesenteric WAT mass. Values are mean ± SE. n = 10 for each group

OH obesity-related hypertension rats induced by high fat diet, BW body weight, HW heart weight, WAT white adipose tissue

* p < 0.05 versus Control; ^#p < 0.05 versus OH